Neuralstem, Inc. Form 8-K September 22, 2014

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 22, 2014

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

Delaware<br/>(State or other jurisdiction of<br/>incorporation or organization)000-135745952-2007292(Commission File No.)(IRS Employee Identification No.)20271 Goldenrod Lane, 2<sup>nd</sup> Floor,

Germantown, Maryland 20876

(Address of Principal Executive Offices)

(301) 366-4960

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Item 8.01. Other Events.

On September 22, 2014 Neuralstem, Inc. ("Company") announced that Jonathan D. Glass, MD, site investigator at Emory University, presented long-term follow up data on the Phase I trial testing NSI-566 human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). A copy of the press release is attached to this report as Exhibit 99.01.

# Item 9.01 Financial Statement and Exhibits.

#### Exhibit Number Description

99.01 Press Release Dated September 22, 2014

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Issuer has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

#### NEURALSTEM, INC

By: \_\_\_\_

I. Richard Garr

Chief Executive Officer

Dated: September 22, 2014

# **INDEX OF EXHIBITS**

# Exhibit Number Description

99.01 Press Release Dated September 22, 2014